| SS.ZUC-Leprfa-/-/Slc |
heart ventricle septal wall thickness |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricle wall thickness |
male |
91.0 days
| 12 |
|
0.16 |
cm |
0.0 |
0.01 |
echocardiography |
0.0 |
|
|
|
|
101786 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle weight to tibia length ratio |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricle mass |
female |
91.0 days
| 7 |
|
0.28 |
g/cm |
0.01 |
0.02 |
post excision weight measurement |
0.0 |
ovariectomy |
42 |
days |
|
101698 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
tibia straight segment length |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
tibia length |
male |
91.0 days
| 13 |
|
34.58 |
mm |
0.15 |
0.54 |
body measuring method |
0.0 |
|
|
|
|
101972 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart weight to tibia length ratio |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart mass |
male |
91.0 days
| 13 |
|
0.43 |
g/cm |
0.01 |
0.04 |
post excision weight measurement |
0.0 |
|
|
|
|
101974 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart weight to tibia length ratio |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart mass |
male |
91.0 days
| 13 |
|
0.42 |
g/cm |
0.01 |
0.04 |
post excision weight measurement |
0.0 |
|
|
|
|
101975 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle weight to tibia length ratio |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle mass |
male |
91.0 days
| 13 |
|
0.31 |
g/cm |
0.01 |
0.03 |
post excision weight measurement |
0.0 |
|
|
|
lv/tl |
101977 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
epididymal fat pad weight to tibia length ratio |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
epididymal fat pad mass |
male |
91.0 days
| 13 |
|
3.58 |
g/cm |
0.12 |
0.42 |
post excision weight measurement |
0.0 |
|
|
|
ef/tl |
101984 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
retroperitoneal fat pad weight to tibia length ratio |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
retroperitoneal fat pad mass |
male |
91.0 days
| 13 |
|
429.56 |
mg/mm |
13.64 |
49.18 |
post excision weight measurement |
0.0 |
|
|
|
rf/tl |
101980 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
body weight |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
body mass |
female |
91.0 days
| 8 |
|
393.0 |
g |
6.0 |
16.97 |
body weighing method |
0.0 |
ovariectomy |
42 |
days |
|
101663 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
body weight |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
body mass |
female |
91.0 days
| 7 |
|
339.0 |
g |
13.0 |
34.39 |
body weighing method |
0.0 |
ovariectomy |
42 |
days |
|
101664 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
calculated heart left ventricle weight |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricle mass |
female |
91.0 days
| 7 |
|
1176.0 |
mg |
46.0 |
121.7 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101726 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
E wave deceleration time |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart pumping trait |
female |
91.0 days
| 7 |
|
59.9 |
ms |
1.0 |
2.65 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101734 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart isovolumetric relaxation time |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart muscle relaxation trait |
female |
91.0 days
| 8 |
|
43.1 |
ms |
1.5 |
4.24 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101737 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
myocardial performance index |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart pumping trait |
female |
91.0 days
| 8 |
|
0.61 |
null |
0.03 |
0.08 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101741 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
left ventricular end-diastolic blood pressure |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricular blood pressure trait |
female |
91.0 days
| 8 |
|
4.43 |
mmHg |
0.21 |
0.59 |
vascular transducer tipped catheter |
0.0 |
ovariectomy |
42 |
days |
|
101745 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
time constant of left ventricular pressure decay |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricular blood pressure trait |
female |
91.0 days
| 7 |
|
62.4 |
ms |
3.3 |
8.73 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101750 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
time constant of left ventricular pressure decay |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricular blood pressure trait |
female |
91.0 days
| 8 |
|
47.3 |
ms |
1.5 |
4.24 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101749 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart weight to tibia length ratio |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart mass |
female |
91.0 days
| 7 |
|
0.35 |
g/cm |
0.0 |
0.0 |
post excision weight measurement |
0.0 |
ovariectomy |
42 |
days |
|
101694 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
pancreas weight to tibia length |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
pancreas mass |
male |
91.0 days
| 7 |
|
28.68 |
mg/mm |
1.66 |
4.39 |
post excision weight measurement |
0.0 |
|
|
|
p/tl |
101835 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
serum total cholesterol level |
fasting (for 16 hours) |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
blood cholesterol amount |
male |
126.0 days
| 7 |
|
371.14 |
mg/dl |
39.21 |
103.74 |
serum total cholesterol measurement test |
0.0 |
|
|
|
|
101920 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
ejection fraction |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
cardiac output trait |
male |
91.0 days
| 7 |
|
82.46 |
% |
1.65 |
4.37 |
echocardiography |
0.0 |
|
|
|
|
101811 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
time constant of left ventricular pressure decay |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricular blood pressure trait |
male |
91.0 days
| 7 |
|
36.72 |
ms |
1.45 |
3.84 |
echocardiography |
0.0 |
|
|
|
|
101827 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
blood high density lipoprotein cholesterol level |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood HDL cholesterol amount |
male |
91.0 days
| 7 |
|
73.0 |
mg/dl |
15.83 |
41.88 |
blood cholesterol analysis |
0.0 |
|
|
|
|
101843 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
blood low density lipoprotein cholesterol level |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood LDL cholesterol amount |
male |
91.0 days
| 12 |
|
38.17 |
mg/dl |
1.53 |
5.3 |
blood cholesterol analysis |
0.0 |
|
|
|
|
101848 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
blood aspartate aminotransferase activity level |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood aspartate transaminase amount |
male |
91.0 days
| 7 |
|
45.0 |
U/l |
3.53 |
9.34 |
automated blood analysis |
0.0 |
|
|
|
|
101859 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
serum creatinine level |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood creatinine amount |
male |
91.0 days
| 12 |
|
0.37 |
mg/dl |
0.03 |
0.1 |
serum creatinine analysis |
0.0 |
|
|
|
|
101876 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
heart rate |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
heart pumping trait |
male |
126.0 days
| 7 |
|
400.73 |
beats/min |
15.4 |
40.74 |
tail cuff plethysmography |
0.0 |
|
|
|
|
101892 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
heart weight to tibia length ratio |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
heart mass |
male |
126.0 days
| 7 |
|
0.42 |
g/cm |
0.0 |
0.01 |
post excision weight measurement |
0.0 |
|
|
|
|
101894 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
both kidneys wet weight to tibia length ratio |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
kidney mass |
male |
126.0 days
| 7 |
|
1.29 |
g/cm |
0.04 |
0.1 |
post excision weight measurement |
0.0 |
|
|
|
|
101902 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
liver weight to tibia length ratio |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
liver mass |
male |
126.0 days
| 7 |
|
600.11 |
mg/mm |
42.14 |
111.49 |
post excision weight measurement |
0.0 |
|
|
|
liv/tl |
101904 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
retroperitoneal fat pad weight to tibia length ratio |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
retroperitoneal fat pad mass |
male |
126.0 days
| 7 |
|
839.28 |
mg/mm |
33.0 |
87.31 |
post excision weight measurement |
0.0 |
|
|
|
rf/tl |
101906 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
serum low density lipoprotein cholesterol level |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood LDL cholesterol amount |
male |
91.0 days
| 7 |
|
57.25 |
mg/dl |
13.15 |
34.79 |
serum low-density lipoprotein-cholesterol measurement test |
0.0 |
|
|
|
|
101946 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
serum triglyceride level |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood triglyceride amount |
male |
91.0 days
| 7 |
|
1190.0 |
mg/dl |
324.22 |
857.81 |
serum triglyceride analysis |
0.0 |
|
|
|
|
101951 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
serum glucose level |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood glucose amount |
male |
91.0 days
| 7 |
|
143.0 |
mg/dl |
14.78 |
39.1 |
serum glucose analysis |
0.0 |
|
|
|
|
101957 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
serum insulin level |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood insulin amount |
male |
91.0 days
| 6 |
|
0.0 |
mg/dl |
0.0 |
0.0 |
serum insulin analysis |
0.0 |
|
|
|
|
101959 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
serum glucose level |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood glucose amount |
male |
91.0 days
| 7 |
|
154.33 |
mg/dl |
15.15 |
40.08 |
serum glucose analysis |
0.0 |
|
|
|
|
101958 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart posterior wall thickness |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle posterior wall thickness |
male |
91.0 days
| 13 |
|
0.2 |
cm |
0.0 |
0.01 |
echocardiography |
0.0 |
|
|
|
|
101999 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
ejection fraction |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
cardiac output trait |
male |
91.0 days
| 13 |
|
79.88 |
% |
1.51 |
5.44 |
echocardiography |
0.0 |
|
|
|
|
102012 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
time constant of left ventricular pressure decay |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricular blood pressure trait |
male |
91.0 days
| 13 |
|
22.53 |
ms |
0.89 |
3.21 |
echocardiography |
0.0 |
|
|
|
|
102021 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
left ventricular end-diastolic blood pressure |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricular blood pressure trait |
male |
91.0 days
| 13 |
|
17.65 |
mmHg |
1.43 |
5.16 |
vascular transducer tipped catheter |
0.0 |
|
|
|
|
102022 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart isovolumetric relaxation time |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart muscle relaxation trait |
male |
91.0 days
| 13 |
|
32.78 |
ms |
1.14 |
4.11 |
echocardiography |
0.0 |
|
|
|
|
102017 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
left ventricular end-diastolic blood pressure |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricular blood pressure trait |
male |
91.0 days
| 13 |
|
8.77 |
mmHg |
1.87 |
6.74 |
vascular transducer tipped catheter |
0.0 |
|
|
|
|
102024 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricular blood pressure trait |
male |
91.0 days
| 13 |
|
2.1 |
mmHg/mm |
0.13 |
0.47 |
vascular transducer tipped catheter |
0.0 |
|
|
|
|
102025 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
single kidney weight to tibia length ratio |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
kidney mass |
male |
91.0 days
| 12 |
|
25.22 |
g/cm |
0.65 |
2.26 |
post excision weight measurement |
0.0 |
|
|
|
|
101770 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
epididymal fat pad weight to tibia length ratio |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
epididymal fat pad mass |
male |
91.0 days
| 12 |
|
2.43 |
g/cm |
0.1 |
0.35 |
post excision weight measurement |
0.0 |
|
|
|
ef/tl |
101778 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
retroperitoneal fat pad weight to tibia length ratio |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
retroperitoneal fat pad mass |
male |
91.0 days
| 12 |
|
334.74 |
mg/mm |
9.21 |
31.9 |
post excision weight measurement |
0.0 |
|
|
|
rf/tl |
101774 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
inguinal fat pad weight to tibia length ratio |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
inguinal fat pad mass |
male |
91.0 days
| 12 |
|
765.81 |
mg/mm |
23.86 |
82.65 |
post excision weight measurement |
0.0 |
|
|
|
if/tl |
101782 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
inguinal fat pad weight to tibia length ratio |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
inguinal fat pad mass |
female |
91.0 days
| 7 |
|
155.0 |
mg/mm |
14.0 |
37.04 |
post excision weight measurement |
0.0 |
ovariectomy |
42 |
days |
sf/tl |
101706 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
inguinal fat pad weight to tibia length ratio |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
inguinal fat pad mass |
male |
91.0 days
| 13 |
|
1448.07 |
mg/mm |
60.58 |
218.42 |
post excision weight measurement |
0.0 |
|
|
|
if/tl |
101990 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
mesenteric fat pad weight to tibia length ratio |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
mesenteric fat pad mass |
male |
91.0 days
| 13 |
|
348.17 |
mg/mm |
9.57 |
34.51 |
post excision weight measurement |
0.0 |
|
|
|
mf/tl, mesenteric fat pad weight to tibia length ratio |
101988 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart ventricle septal wall thickness |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle wall thickness |
male |
91.0 days
| 13 |
|
0.2 |
cm |
0.0 |
0.01 |
echocardiography |
0.0 |
|
|
|
|
101993 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart rate |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart pumping trait |
female |
91.0 days
| 8 |
|
339.0 |
beats/min |
11.0 |
31.11 |
tail cuff plethysmography |
0.0 |
ovariectomy |
42 |
days |
|
101675 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
systolic blood pressure |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
arterial blood pressure trait |
female |
91.0 days
| 8 |
undefined |
221.0 |
mmHg |
5.0 |
14.14 |
tail cuff plethysmography |
0.0 |
ovariectomy |
42 |
days |
|
101671 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
systolic blood pressure |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
arterial blood pressure trait |
female |
91.0 days
| 7 |
undefined |
202.0 |
mmHg |
6.0 |
15.87 |
tail cuff plethysmography |
0.0 |
ovariectomy |
42 |
days |
|
101672 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle fractional shortening |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricle end-diastolic diameter |
female |
91.0 days
| 7 |
|
61.3 |
% |
2.7 |
7.14 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101722 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle relative wall thickness |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricle wall thickness |
female |
91.0 days
| 8 |
|
57.0 |
% |
2.0 |
5.66 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101729 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle relative wall thickness |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricle wall thickness |
male |
91.0 days
| 7 |
|
57.0 |
% |
4.0 |
10.58 |
echocardiography |
0.0 |
|
|
|
|
101803 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricular blood pressure trait |
male |
91.0 days
| 9 |
|
0.65 |
mmHg/mm |
0.05 |
0.15 |
echocardiography |
0.0 |
|
|
|
lvedp/lvdd |
101832 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
pancreas weight to tibia length |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
pancreas mass |
male |
91.0 days
| 12 |
|
29.85 |
mg/mm |
1.97 |
6.82 |
post excision weight measurement |
0.0 |
|
|
|
p/tl |
101836 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
serum triglyceride level |
fasting (for 16 hours) |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
blood triglyceride amount |
male |
126.0 days
| 7 |
|
1559.93 |
mg/dl |
353.89 |
936.3 |
serum triglyceride analysis |
0.0 |
|
|
|
|
101918 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
serum high density lipoprotein cholesterol level |
fasting (for 16 hours) |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
blood HDL cholesterol amount |
male |
126.0 days
| 7 |
|
50.14 |
mg/dl |
2.3 |
6.09 |
serum high-density lipoprotein-cholesterol measurement test |
0.0 |
|
|
|
|
101924 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
creatinine clearance to total kidney weight ratio |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
glomerular filtration trait |
male |
126.0 days
| 7 |
|
0.2 |
ml/min/g |
0.03 |
0.08 |
urine creatinine analysis |
0.0 |
|
|
|
|
101938 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle fractional shortening |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricle end-diastolic diameter |
male |
91.0 days
| 7 |
|
44.43 |
% |
1.71 |
4.52 |
echocardiography |
0.0 |
|
|
|
|
101807 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle fractional shortening |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricle end-diastolic diameter |
male |
91.0 days
| 12 |
|
38.55 |
% |
1.09 |
3.78 |
echocardiography |
0.0 |
|
|
|
|
101808 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
E/A wave ratio |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood flow trait |
male |
91.0 days
| 7 |
|
1.54 |
null |
0.13 |
0.34 |
echocardiography |
0.0 |
|
|
|
|
101815 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
blood high density lipoprotein cholesterol level |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood HDL cholesterol amount |
male |
91.0 days
| 12 |
|
67.83 |
mg/dl |
15.23 |
52.76 |
blood cholesterol analysis |
0.0 |
|
|
|
|
101844 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
blood low density lipoprotein cholesterol level |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood LDL cholesterol amount |
male |
91.0 days
| 7 |
|
44.25 |
mg/dl |
2.4 |
6.35 |
blood cholesterol analysis |
0.0 |
|
|
|
|
101847 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
serum free fatty acids level |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood free fatty acid amount |
male |
91.0 days
| 7 |
|
30.61 |
mmol/l |
8.11 |
21.46 |
serum free fatty acid analysis |
0.0 |
|
|
|
**suspected wrong units in paper(mg/dl) |
101855 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
serum free fatty acids level |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood free fatty acid amount |
male |
91.0 days
| 12 |
|
19.47 |
mmol/l |
1.16 |
4.02 |
serum free fatty acid analysis |
0.0 |
|
|
|
**suspected wrong units in paper(mg/dl) |
101856 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
blood alanine aminotransferase activity level |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood alanine transaminase amount |
male |
91.0 days
| 12 |
|
46.67 |
U/l |
2.44 |
8.45 |
automated blood analysis |
0.0 |
|
|
|
|
101864 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
creatinine clearance to total kidney weight ratio |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
glomerular filtration trait |
male |
91.0 days
| 12 |
|
0.28 |
ml/min/g |
0.04 |
0.14 |
serum creatinine analysis |
0.0 |
|
|
|
|
101884 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
systolic blood pressure |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
arterial blood pressure trait |
male |
126.0 days
| 7 |
|
210.62 |
mmHg |
2.54 |
6.72 |
tail cuff plethysmography |
0.0 |
|
|
|
|
101890 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
ratio of survivors of metabolic syndrome to total study population during a period of time |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
total life span |
male |
126.0 days
| 20 |
|
35.0 |
% |
|
|
necropsy |
0.0 |
|
|
|
ratio of survivors of metabolic syndrome to total study population during a period of time (CMO:0003803) |
101910 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
inguinal fat pad weight to tibia length ratio |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
inguinal fat pad mass |
male |
126.0 days
| 7 |
|
795.02 |
mg/mm |
41.33 |
109.35 |
post excision weight measurement |
0.0 |
|
|
|
if/tl |
101908 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
serum total cholesterol level |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood cholesterol amount |
male |
91.0 days
| 7 |
|
218.0 |
mg/dl |
26.0 |
68.79 |
serum total cholesterol measurement test |
0.0 |
|
|
|
|
101942 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
serum total cholesterol level |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood cholesterol amount |
male |
91.0 days
| 7 |
|
200.33 |
mg/dl |
44.7 |
118.27 |
serum total cholesterol measurement test |
0.0 |
|
|
|
|
101943 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
serum triglyceride level |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood triglyceride amount |
male |
91.0 days
| 6 |
|
2196.13 |
mg/dl |
204.52 |
500.97 |
serum triglyceride analysis |
0.0 |
|
|
|
|
101950 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
serum glucose level |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood glucose amount |
male |
91.0 days
| 6 |
|
149.4 |
mg/dl |
12.36 |
30.28 |
serum glucose analysis |
0.0 |
|
|
|
|
101956 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
serum triglyceride level |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood triglyceride amount |
male |
91.0 days
| 7 |
|
980.67 |
mg/dl |
302.75 |
801.0 |
serum triglyceride analysis |
0.0 |
|
|
|
|
101952 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle end-diastolic diameter |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle end-diastolic diameter |
male |
91.0 days
| 13 |
|
8.43 |
mm |
0.11 |
0.4 |
echocardiography |
0.0 |
|
|
|
|
101997 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle relative wall thickness |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle wall thickness |
male |
91.0 days
| 13 |
|
49.0 |
% |
1.0 |
3.61 |
echocardiography |
0.0 |
|
|
|
|
102004 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle relative wall thickness |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle wall thickness |
male |
91.0 days
| 13 |
|
47.0 |
% |
2.0 |
7.21 |
echocardiography |
0.0 |
|
|
|
|
102006 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle fractional shortening |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle end-diastolic diameter |
male |
91.0 days
| 13 |
|
47.66 |
% |
2.43 |
8.76 |
echocardiography |
0.0 |
|
|
|
|
102007 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
ejection fraction |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
cardiac output trait |
male |
91.0 days
| 13 |
|
82.5 |
% |
1.94 |
6.99 |
echocardiography |
0.0 |
|
|
|
|
102010 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
ejection fraction |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
cardiac output trait |
male |
91.0 days
| 13 |
|
79.33 |
% |
1.21 |
4.36 |
echocardiography |
0.0 |
|
|
|
|
102011 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
E wave deceleration time |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood flow trait |
male |
91.0 days
| 13 |
|
46.93 |
ms |
1.06 |
3.82 |
echocardiography |
0.0 |
|
|
|
|
102014 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricular blood pressure trait |
male |
91.0 days
| 13 |
|
1.2 |
mmHg/mm |
0.25 |
0.9 |
vascular transducer tipped catheter |
0.0 |
|
|
|
|
102026 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
epididymal fat pad weight to tibia length ratio |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
epididymal fat pad mass |
male |
91.0 days
| 7 |
|
3.17 |
g/cm |
0.12 |
0.32 |
post excision weight measurement |
0.0 |
|
|
|
ef/tl |
101777 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle posterior wall thickness |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricle posterior wall thickness |
male |
91.0 days
| 7 |
|
2.16 |
mm |
0.09 |
0.24 |
echocardiography |
0.0 |
|
|
|
|
101793 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle posterior wall thickness |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricle posterior wall thickness |
male |
91.0 days
| 12 |
|
1.68 |
mm |
0.05 |
0.17 |
echocardiography |
0.0 |
|
|
|
|
101794 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
retroperitoneal fat pad weight to tibia length ratio |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
retroperitoneal fat pad mass |
female |
91.0 days
| 8 |
|
482.0 |
mg/mm |
18.0 |
50.91 |
post excision weight measurement |
0.0 |
ovariectomy |
42 |
days |
vf/tl |
101701 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
tibia straight segment length |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
tibia length |
male |
91.0 days
| 13 |
|
34.52 |
mm |
0.21 |
0.76 |
body measuring method |
0.0 |
|
|
|
|
101973 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart weight to tibia length ratio |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart mass |
male |
91.0 days
| 13 |
|
0.43 |
g/cm |
0.01 |
0.04 |
post excision weight measurement |
0.0 |
|
|
|
|
101976 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
epididymal fat pad weight to tibia length ratio |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
epididymal fat pad mass |
male |
91.0 days
| 13 |
|
3.55 |
g/cm |
0.1 |
0.35 |
post excision weight measurement |
0.0 |
|
|
|
ef/tl |
101983 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
tibia straight segment length |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
tibia length |
female |
91.0 days
| 8 |
|
32.5 |
mm |
0.9 |
2.55 |
body length measuring method |
0.0 |
ovariectomy |
42 |
days |
|
101667 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle end-diastolic diameter |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricle end-diastolic diameter |
female |
91.0 days
| 7 |
|
7.1 |
mm |
0.12 |
0.32 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101718 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart isovolumetric relaxation time |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart muscle relaxation trait |
female |
91.0 days
| 7 |
|
57.9 |
ms |
4.2 |
11.11 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101738 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
left ventricular end-diastolic blood pressure |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricular blood pressure trait |
female |
91.0 days
| 7 |
|
5.91 |
mmHg |
0.18 |
0.48 |
vascular transducer tipped catheter |
0.0 |
ovariectomy |
42 |
days |
|
101746 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricular blood pressure trait |
female |
91.0 days
| 8 |
|
0.63 |
mmHg/mm |
0.05 |
0.14 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101753 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart weight to tibia length ratio |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart mass |
female |
91.0 days
| 8 |
|
0.35 |
g/cm |
0.0 |
0.0 |
post excision weight measurement |
0.0 |
ovariectomy |
42 |
days |
|
101693 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart weight to tibia length ratio |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart mass |
male |
91.0 days
| 12 |
|
0.34 |
g/cm |
0.0 |
0.0 |
post excision weight measurement |
0.0 |
|
|
|
|
101758 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
liver weight to tibia length ratio |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
liver mass |
male |
91.0 days
| 12 |
|
568.94 |
mg/mm |
19.5 |
67.55 |
post excision weight measurement |
0.0 |
|
|
|
liv/tl |
101766 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle relative wall thickness |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricle wall thickness |
male |
91.0 days
| 12 |
|
41.0 |
% |
1.0 |
3.46 |
echocardiography |
0.0 |
|
|
|
|
101804 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
serum glucose level |
fasting (for 16 hours) |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
blood glucose amount |
male |
126.0 days
| 7 |
|
136.33 |
mg/dl |
5.27 |
13.94 |
serum glucose analysis |
0.0 |
|
|
|
|
101914 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
serum aspartate aminotransferase activity level |
fasting (for 16 hours) |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
blood aspartate transaminase amount |
male |
126.0 days
| 7 |
|
67.33 |
U/l |
4.67 |
12.36 |
automated blood analysis |
0.0 |
|
|
|
|
101928 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
urine protein level |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
total urine protein amount |
male |
126.0 days
| 7 |
|
735.52 |
mg/d |
93.97 |
248.62 |
urine protein analysis |
0.0 |
|
|
|
|
101936 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
ejection fraction |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
cardiac output trait |
male |
91.0 days
| 12 |
|
76.47 |
% |
1.2 |
4.16 |
echocardiography |
0.0 |
|
|
|
|
101812 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
E/A wave ratio |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood flow trait |
male |
91.0 days
| 12 |
|
1.91 |
null |
0.07 |
0.24 |
echocardiography |
0.0 |
|
|
|
e/a |
101816 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
time constant of left ventricular pressure decay |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricular blood pressure trait |
male |
91.0 days
| 12 |
|
28.77 |
ms |
1.73 |
5.99 |
echocardiography |
0.0 |
|
|
|
|
101828 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
blood aspartate aminotransferase activity level |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood aspartate transaminase amount |
male |
91.0 days
| 12 |
|
65.6 |
U/l |
7.65 |
26.5 |
automated blood analysis |
0.0 |
|
|
|
|
101860 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
urine total protein level |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
total urine protein amount |
male |
91.0 days
| 12 |
|
13.37 |
mg/ml |
0.97 |
3.35 |
urine protein analysis |
0.0 |
|
|
|
|
101872 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
serum creatinine level |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood creatinine amount |
male |
91.0 days
| 7 |
|
0.34 |
mg/dl |
0.04 |
0.11 |
serum creatinine analysis |
0.0 |
|
|
|
|
101875 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
creatinine clearance to body weight ratio |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
glomerular filtration trait |
male |
91.0 days
| 12 |
|
0.17 |
ml/min/100g |
0.02 |
0.07 |
serum creatinine analysis |
0.0 |
|
|
|
|
101880 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
creatinine clearance to total kidney weight ratio |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
glomerular filtration trait |
male |
91.0 days
| 7 |
|
0.4 |
ml/min/g |
0.03 |
0.08 |
serum creatinine analysis |
0.0 |
|
|
|
|
101883 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle weight to tibia length ratio |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
heart left ventricle mass |
male |
126.0 days
| 7 |
|
0.33 |
g/cm |
0.0 |
0.01 |
post excision weight measurement |
0.0 |
|
|
|
lv/tl |
101896 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle weight to right ventricle weight ratio |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
heart left ventricle mass |
male |
126.0 days
| 7 |
|
4.74 |
null |
0.12 |
0.32 |
post excision weight measurement |
0.0 |
|
|
|
lv/rv |
101898 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
serum free fatty acids level |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood free fatty acid amount |
male |
91.0 days
| 7 |
|
0.59 |
mmol/l |
0.03 |
0.08 |
serum free fatty acid analysis |
0.0 |
|
|
|
|
101955 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
serum insulin level |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood insulin amount |
male |
91.0 days
| 7 |
|
0.0 |
mg/dl |
0.0 |
0.0 |
serum insulin analysis |
0.0 |
|
|
|
|
101960 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart posterior wall thickness |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle posterior wall thickness |
male |
91.0 days
| 13 |
|
0.2 |
cm |
0.01 |
0.02 |
echocardiography |
0.0 |
|
|
|
|
102000 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart isovolumetric relaxation time |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart muscle relaxation trait |
male |
91.0 days
| 13 |
|
29.2 |
ms |
1.79 |
6.45 |
echocardiography |
0.0 |
|
|
|
|
102018 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
time constant of left ventricular pressure decay |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricular blood pressure trait |
male |
91.0 days
| 13 |
|
33.52 |
ms |
1.09 |
3.93 |
echocardiography |
0.0 |
|
|
|
|
102019 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
single kidney weight to tibia length ratio |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
kidney mass |
male |
91.0 days
| 7 |
|
33.51 |
g/cm |
0.99 |
2.62 |
post excision weight measurement |
0.0 |
|
|
|
|
101769 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
retroperitoneal fat pad weight to tibia length ratio |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
retroperitoneal fat pad mass |
male |
91.0 days
| 7 |
|
399.11 |
mg/mm |
19.55 |
51.72 |
post excision weight measurement |
0.0 |
|
|
|
rf/tl |
101773 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle end-diastolic diameter |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricle end-diastolic diameter |
male |
91.0 days
| 7 |
|
7.58 |
mm |
0.2 |
0.53 |
echocardiography |
0.0 |
|
|
|
|
101789 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
calculated heart left ventricle weight |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricle mass |
male |
91.0 days
| 12 |
|
986.71 |
mg |
25.23 |
87.4 |
echocardiography |
0.0 |
|
|
|
|
101798 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle weight to tibia length ratio |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricle mass |
female |
91.0 days
| 8 |
|
0.28 |
g/cm |
0.01 |
0.02 |
post excision weight measurement |
0.0 |
ovariectomy |
42 |
days |
lv/tl |
101697 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
inguinal fat pad weight to tibia length ratio |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
inguinal fat pad mass |
female |
91.0 days
| 8 |
|
209.0 |
mg/mm |
12.0 |
33.94 |
post excision weight measurement |
0.0 |
ovariectomy |
42 |
days |
sf/tl |
101705 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart ventricle septal wall thickness |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricle wall thickness |
female |
91.0 days
| 8 |
|
0.21 |
cm |
0.0 |
0.01 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101709 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart ventricle septal wall thickness |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricle wall thickness |
female |
91.0 days
| 7 |
|
0.21 |
cm |
0.01 |
0.01 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101710 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
tibia straight segment length |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
tibia length |
male |
91.0 days
| 13 |
|
34.62 |
mm |
0.15 |
0.54 |
body measuring method |
0.0 |
|
|
|
|
101971 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle weight to tibia length ratio |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle mass |
male |
91.0 days
| 13 |
|
0.31 |
g/cm |
0.01 |
0.03 |
post excision weight measurement |
0.0 |
|
|
|
lv/tl |
101979 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
epididymal fat pad weight to tibia length ratio |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
epididymal fat pad mass |
male |
91.0 days
| 13 |
|
3.62 |
g/cm |
0.09 |
0.34 |
post excision weight measurement |
0.0 |
|
|
|
ef/tl |
101985 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
mesenteric fat pad weight to tibia length ratio |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
mesenteric fat pad mass |
male |
91.0 days
| 13 |
|
364.22 |
mg/mm |
10.33 |
37.25 |
post excision weight measurement |
0.0 |
|
|
|
mf/tl |
101986 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
inguinal fat pad weight to tibia length ratio |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
inguinal fat pad mass |
male |
91.0 days
| 13 |
|
1482.16 |
mg/mm |
53.88 |
194.27 |
post excision weight measurement |
0.0 |
|
|
|
if/tl |
101991 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle end-diastolic diameter |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle end-diastolic diameter |
male |
91.0 days
| 13 |
|
8.27 |
mm |
0.13 |
0.47 |
echocardiography |
0.0 |
|
|
|
|
101995 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
tibia straight segment length |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
tibia length |
female |
91.0 days
| 7 |
|
31.8 |
mm |
0.6 |
1.59 |
body length measuring method |
0.0 |
ovariectomy |
42 |
days |
|
101668 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle posterior wall thickness |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricle posterior wall thickness |
female |
91.0 days
| 8 |
|
2.06 |
mm |
0.04 |
0.11 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101713 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle posterior wall thickness |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricle posterior wall thickness |
female |
91.0 days
| 7 |
|
2.16 |
mm |
0.06 |
0.16 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101714 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
calculated heart left ventricle weight |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricle mass |
female |
91.0 days
| 8 |
|
1114.0 |
mg |
35.0 |
98.99 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101725 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle relative wall thickness |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricle wall thickness |
female |
91.0 days
| 7 |
|
61.0 |
% |
2.0 |
5.29 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101730 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
myocardial performance index |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart pumping trait |
female |
91.0 days
| 7 |
|
0.99 |
null |
0.03 |
0.08 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101742 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle weight to tibia length ratio |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricle mass |
male |
91.0 days
| 7 |
|
0.32 |
g/cm |
0.01 |
0.01 |
post excision weight measurement |
0.0 |
|
|
|
lv/tl |
101761 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
liver weight to tibia length ratio |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
liver mass |
male |
91.0 days
| 7 |
|
612.89 |
mg/mm |
31.39 |
83.05 |
post excision weight measurement |
0.0 |
|
|
|
liv/tl |
101765 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
serum leptin level |
fasting (for 16 hours) |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
blood leptin amount |
male |
126.0 days
| 7 |
|
53.97 |
ng/ml |
2.34 |
6.19 |
enzyme linked immunosorbent assay |
0.0 |
|
|
|
|
101912 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
serum insulin level |
fasting (for 16 hours) |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
blood insulin amount |
male |
126.0 days
| 7 |
|
0.0 |
mg/dl |
0.0 |
0.0 |
enzyme linked immunosorbent assay |
0.0 |
|
|
|
|
101916 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
serum low density lipoprotein cholesterol to high density lipoprotein cholesterol ratio |
fasting (for 16 hours) |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
blood cholesterol amount |
male |
126.0 days
| 6 |
|
1.59 |
null |
0.15 |
0.37 |
serum high-density lipoprotein-cholesterol measurement test |
0.0 |
|
|
|
ldl/hdl |
101926 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
serum urea nitrogen level |
fasting (for 16 hours) |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
blood urea nitrogen amount |
male |
126.0 days
| 7 |
|
76.21 |
mg/dl |
13.56 |
35.88 |
serum urea nitrogen analysis |
0.0 |
|
|
|
|
101932 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
creatinine clearance to body weight ratio |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
glomerular filtration trait |
male |
126.0 days
| 7 |
|
0.18 |
ml/min/100g |
0.02 |
0.05 |
urine creatinine analysis |
0.0 |
|
|
|
|
101940 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
heart isovolumetric relaxation time |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart muscle relaxation trait |
male |
91.0 days
| 7 |
|
38.35 |
ms |
1.84 |
4.87 |
echocardiography |
0.0 |
|
|
|
|
101823 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
blood total cholesterol level |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood cholesterol amount |
male |
91.0 days
| 7 |
|
329.25 |
mg/dl |
52.32 |
138.43 |
blood cholesterol analysis |
0.0 |
|
|
|
|
101839 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
blood total cholesterol level |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood cholesterol amount |
male |
91.0 days
| 12 |
|
297.67 |
mg/dl |
35.78 |
123.95 |
blood cholesterol analysis |
0.0 |
|
|
|
|
101840 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
serum urea nitrogen level |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood urea nitrogen amount |
male |
91.0 days
| 12 |
|
27.42 |
mg/dl |
1.23 |
4.26 |
serum urea nitrogen analysis |
0.0 |
|
|
|
|
101868 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
serum urea nitrogen level |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood urea nitrogen amount |
male |
91.0 days
| 7 |
|
23.17 |
mg/dl |
0.28 |
0.74 |
serum urea nitrogen analysis |
0.0 |
|
|
|
|
101867 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
tibia straight segment length |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
tibia length |
male |
126.0 days
| 7 |
|
36.47 |
mm |
0.12 |
0.32 |
body measuring method |
0.0 |
|
|
|
|
101888 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
serum low density lipoprotein cholesterol level |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood LDL cholesterol amount |
male |
91.0 days
| 6 |
|
102.5 |
mg/dl |
9.37 |
22.95 |
serum low-density lipoprotein-cholesterol measurement test |
0.0 |
|
|
|
|
101944 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
serum high density lipoprotein cholesterol level |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood HDL cholesterol amount |
male |
91.0 days
| 6 |
|
97.25 |
mg/dl |
15.33 |
37.55 |
serum high-density lipoprotein-cholesterol measurement test |
0.0 |
|
|
|
|
101947 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
serum high density lipoprotein cholesterol level |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood HDL cholesterol amount |
male |
91.0 days
| 7 |
|
99.71 |
mg/dl |
5.83 |
15.42 |
serum high-density lipoprotein-cholesterol measurement test |
0.0 |
|
|
|
|
101949 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
serum high density lipoprotein cholesterol level |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood HDL cholesterol amount |
male |
91.0 days
| 7 |
|
94.83 |
mg/dl |
6.35 |
16.8 |
serum high-density lipoprotein-cholesterol measurement test |
0.0 |
|
|
|
|
101948 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
serum free fatty acids level |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood free fatty acid amount |
male |
91.0 days
| 6 |
|
1.42 |
mmol/l |
0.14 |
0.34 |
serum free fatty acid analysis |
0.0 |
|
|
|
|
101953 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart posterior wall thickness |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle posterior wall thickness |
male |
91.0 days
| 13 |
|
0.21 |
cm |
0.01 |
0.02 |
echocardiography |
0.0 |
|
|
|
|
101998 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle fractional shortening |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle end-diastolic diameter |
male |
91.0 days
| 13 |
|
44.28 |
% |
1.6 |
5.77 |
echocardiography |
0.0 |
|
|
|
|
102009 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle fractional shortening |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle end-diastolic diameter |
male |
91.0 days
| 13 |
|
43.53 |
% |
1.18 |
4.25 |
echocardiography |
0.0 |
|
|
|
|
102008 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart isovolumetric relaxation time |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart muscle relaxation trait |
male |
91.0 days
| 13 |
|
40.75 |
ms |
2.42 |
8.73 |
echocardiography |
0.0 |
|
|
|
|
102016 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
E wave deceleration time |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood flow trait |
male |
91.0 days
| 13 |
|
43.5 |
ms |
1.57 |
5.66 |
echocardiography |
0.0 |
|
|
|
|
102015 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
E wave deceleration time |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood flow trait |
male |
91.0 days
| 13 |
|
53.05 |
ms |
1.48 |
5.34 |
echocardiography |
0.0 |
|
|
|
|
102013 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
time constant of left ventricular pressure decay |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricular blood pressure trait |
male |
91.0 days
| 13 |
|
25.89 |
ms |
1.53 |
5.52 |
echocardiography |
0.0 |
|
|
|
|
102020 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricular blood pressure trait |
male |
91.0 days
| 13 |
|
1.05 |
mmHg/mm |
0.24 |
0.87 |
vascular transducer tipped catheter |
0.0 |
|
|
|
|
102027 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
inguinal fat pad weight to tibia length ratio |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
inguinal fat pad mass |
male |
91.0 days
| 7 |
|
1105.49 |
mg/mm |
59.28 |
156.84 |
post excision weight measurement |
0.0 |
|
|
|
if/tl |
101781 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
heart ventricle septal wall thickness |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricle wall thickness |
male |
91.0 days
| 7 |
|
0.21 |
cm |
0.01 |
0.03 |
echocardiography |
0.0 |
|
|
|
|
101785 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle end-diastolic diameter |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricle end-diastolic diameter |
male |
91.0 days
| 12 |
|
8.05 |
mm |
0.07 |
0.24 |
echocardiography |
0.0 |
|
|
|
|
101790 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
calculated heart left ventricle weight |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricle mass |
male |
91.0 days
| 7 |
|
1286.0 |
mg |
64.26 |
170.02 |
echocardiography |
0.0 |
|
|
|
|
101797 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
retroperitoneal fat pad weight to tibia length ratio |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
retroperitoneal fat pad mass |
female |
91.0 days
| 7 |
|
377.0 |
mg/mm |
33.0 |
87.31 |
post excision weight measurement |
0.0 |
ovariectomy |
42 |
days |
|
101702 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle weight to tibia length ratio |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle mass |
male |
91.0 days
| 13 |
|
0.3 |
g/cm |
0.01 |
0.03 |
post excision weight measurement |
0.0 |
|
|
|
lv/tl |
101978 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
retroperitoneal fat pad weight to tibia length ratio |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
retroperitoneal fat pad mass |
male |
91.0 days
| 13 |
|
415.13 |
mg/mm |
12.15 |
43.81 |
post excision weight measurement |
0.0 |
|
|
|
rf/tl |
101981 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
retroperitoneal fat pad weight to tibia length ratio |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
retroperitoneal fat pad mass |
male |
91.0 days
| 13 |
|
429.58 |
mg/mm |
14.03 |
50.59 |
post excision weight measurement |
0.0 |
|
|
|
rf/tl |
101982 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
mesenteric fat pad weight to tibia length ratio |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
mesenteric fat pad mass |
male |
91.0 days
| 13 |
|
371.46 |
mg/mm |
9.6 |
34.61 |
post excision weight measurement |
0.0 |
|
|
|
mf/tl |
101987 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
inguinal fat pad weight to tibia length ratio |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
inguinal fat pad mass |
male |
91.0 days
| 13 |
|
1501.32 |
mg/mm |
68.53 |
247.09 |
post excision weight measurement |
0.0 |
|
|
|
if/tl |
101989 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart ventricle septal wall thickness |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle wall thickness |
male |
91.0 days
| 13 |
|
0.2 |
cm |
0.0 |
0.01 |
echocardiography |
0.0 |
|
|
|
|
101994 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart ventricle septal wall thickness |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle wall thickness |
male |
91.0 days
| 13 |
|
0.21 |
cm |
0.0 |
0.01 |
echocardiography |
0.0 |
|
|
|
|
101992 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle end-diastolic diameter |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle end-diastolic diameter |
male |
91.0 days
| 13 |
|
8.56 |
mm |
0.08 |
0.29 |
echocardiography |
0.0 |
|
|
|
|
101996 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart rate |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart pumping trait |
female |
91.0 days
| 7 |
|
366.0 |
beats/min |
8.0 |
21.17 |
tail cuff plethysmography |
0.0 |
ovariectomy |
42 |
days |
|
101676 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle end-diastolic diameter |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricle end-diastolic diameter |
female |
91.0 days
| 8 |
|
7.2 |
mm |
0.14 |
0.4 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101717 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle fractional shortening |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricle end-diastolic diameter |
female |
91.0 days
| 8 |
|
47.7 |
% |
1.9 |
5.37 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101721 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
E wave deceleration time |
bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart pumping trait |
female |
91.0 days
| 8 |
|
56.9 |
ms |
1.8 |
5.09 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101733 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio |
bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) |
Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. |
heart left ventricular blood pressure trait |
female |
91.0 days
| 7 |
|
0.81 |
mmHg/mm |
0.03 |
0.08 |
echocardiography |
0.0 |
ovariectomy |
42 |
days |
|
101754 |
2622 |
| SS.ZUC-Leprfa-/-/Slc |
heart weight to tibia length ratio |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart mass |
male |
91.0 days
| 7 |
|
0.43 |
g/cm |
0.01 |
0.0 |
post excision weight measurement |
0.0 |
|
|
|
|
101757 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle weight to tibia length ratio |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricle mass |
male |
91.0 days
| 12 |
|
0.25 |
g/cm |
0.0 |
0.01 |
post excision weight measurement |
0.0 |
|
|
|
lv/tl |
101762 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart left ventricular blood pressure trait |
male |
91.0 days
| 3 |
|
1.08 |
mmHg/mm |
0.11 |
0.19 |
echocardiography |
0.0 |
|
|
|
lvedp/lvdd |
101831 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
serum low density lipoprotein cholesterol level |
fasting (for 16 hours) |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
blood LDL cholesterol amount |
male |
126.0 days
| 7 |
|
73.85 |
mg/dl |
7.15 |
18.92 |
serum low-density lipoprotein-cholesterol measurement test |
0.0 |
|
|
|
|
101922 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
serum alanine aminotransferase activity level |
fasting (for 16 hours) |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
blood alanine transaminase amount |
male |
126.0 days
| 7 |
|
39.25 |
U/l |
2.63 |
6.96 |
automated blood analysis |
0.0 |
|
|
|
|
101930 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
serum creatinine level |
fasting (for 16 hours) |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
blood creatinine amount |
male |
126.0 days
| 7 |
|
1.09 |
mg/dl |
0.19 |
0.5 |
serum creatinine analysis |
0.0 |
|
|
|
|
101934 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
E wave deceleration time |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood flow trait |
male |
91.0 days
| 7 |
|
43.45 |
ms |
1.23 |
3.25 |
echocardiography |
0.0 |
|
|
|
|
101819 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
E wave deceleration time |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood flow trait |
male |
91.0 days
| 12 |
|
35.82 |
ms |
0.68 |
2.36 |
echocardiography |
0.0 |
|
|
|
|
101820 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
heart isovolumetric relaxation time |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
heart muscle relaxation trait |
male |
91.0 days
| 12 |
|
34.39 |
ms |
1.07 |
3.71 |
echocardiography |
0.0 |
|
|
|
|
101824 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
serum triglyceride level |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood triglyceride amount |
male |
91.0 days
| 7 |
|
1885.5 |
mg/dl |
325.31 |
860.69 |
serum triglyceride analysis |
0.0 |
|
|
|
|
101851 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
serum triglyceride level |
everolimus (0.83 mg/kg/d) (for 28 days) |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood triglyceride amount |
male |
91.0 days
| 12 |
|
1251.33 |
mg/dl |
276.6 |
958.17 |
serum triglyceride analysis |
0.0 |
|
|
|
|
101852 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
blood alanine aminotransferase activity level |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood alanine transaminase amount |
male |
91.0 days
| 7 |
|
33.75 |
U/l |
3.75 |
9.92 |
automated blood analysis |
0.0 |
|
|
|
|
101863 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
urine total protein level |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
total urine protein amount |
male |
91.0 days
| 7 |
|
15.51 |
mg/ml |
1.69 |
4.46 |
urine protein analysis |
0.0 |
|
|
|
|
101871 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
creatinine clearance to body weight ratio |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
glomerular filtration trait |
male |
91.0 days
| 7 |
|
0.28 |
ml/min/100g |
0.03 |
0.08 |
serum creatinine analysis |
0.0 |
|
|
|
|
101879 |
2641 |
| SS.ZUC-Leprfa-/-/Slc |
body weight |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
body mass |
male |
126.0 days
| 7 |
|
536.92 |
g |
6.98 |
18.47 |
body weighing method |
0.0 |
|
|
|
|
101886 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
heart left atrium weight to tibia length ratio |
control condition |
Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. |
heart left atrium mass |
male |
126.0 days
| 7 |
|
2.55 |
mg/mm |
0.14 |
0.37 |
post excision weight measurement |
0.0 |
|
|
|
a/tl |
101900 |
2642 |
| SS.ZUC-Leprfa-/-/Slc |
serum total cholesterol level |
vehicle control condition (0.5 %) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood cholesterol amount |
male |
91.0 days
| 6 |
|
333.0 |
mg/dl |
15.6 |
38.21 |
serum total cholesterol measurement test |
0.0 |
|
|
|
|
101941 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
serum low density lipoprotein cholesterol level |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood LDL cholesterol amount |
male |
91.0 days
| 7 |
|
66.0 |
mg/dl |
9.1 |
24.08 |
serum low-density lipoprotein-cholesterol measurement test |
0.0 |
|
|
|
|
101945 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
serum free fatty acids level |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood free fatty acid amount |
male |
91.0 days
| 7 |
|
0.61 |
mmol/l |
0.05 |
0.13 |
serum free fatty acid analysis |
0.0 |
|
|
|
|
101954 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
serum insulin level |
atorvastatin (20 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
blood insulin amount |
male |
91.0 days
| 7 |
|
0.0 |
mg/dl |
0.0 |
0.0 |
serum insulin analysis |
0.0 |
|
|
|
|
101961 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
heart left ventricle relative wall thickness |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricle wall thickness |
male |
91.0 days
| 13 |
|
46.0 |
% |
1.0 |
3.61 |
echocardiography |
0.0 |
|
|
|
|
102005 |
2644 |
| SS.ZUC-Leprfa-/-/Slc |
left ventricular end-diastolic blood pressure |
atorvastatin (6 mg/kg/d) (for 28 days) |
Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. |
heart left ventricular blood pressure trait |
male |
91.0 days
| 13 |
|
10.39 |
mmHg |
2.03 |
7.32 |
vascular transducer tipped catheter |
0.0 |
|
|
|
|
102023 |
2644 |
